ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
12/18/201408:51:07Merck Acquires OncoEthix for Up to $375 Million
12/09/201416:08:36Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling...
12/09/201415:54:02MARKET SNAPSHOT: The S&P 500 Recorded Its Biggest Drop In Nearly...
12/09/201415:50:44Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling
12/08/201422:16:42Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update
12/08/201419:12:00Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update
12/08/201419:11:47Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update
12/08/201419:04:54MARKET SNAPSHOT: Energy Companies Drag U.S. Stocks Lower
12/08/201418:56:04Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 3rd Update
12/08/201418:54:55U.S. Stocks Down
12/08/201418:51:53Correction to U.S. Stocks Story
12/08/201418:51:25U.S. Stocks Edge Lower
12/08/201418:49:08Correction to Merck-Cubist Deal Story
12/08/201418:02:18MARKET SNAPSHOT: U.S. Stocks: Futures Fall As Global Growth Concerns...
12/08/201412:39:54MARKET SNAPSHOT: U.S. Stocks: Futures Falling, With Dow Poised...
11/24/201409:57:19Bristol-Myers, Five Prime to Collaborate on Immunotherapy
11/17/201411:41:20U.S. Stocks Bounce Back from Early Loses
11/17/201405:11:44Pfizer, Germany's Merck to Develop Tumor Treatment -- Update
10/27/201416:37:41MARKET SNAPSHOT: Energy Stocks Sap S&P 500
10/27/201414:06:16MARKET SNAPSHOT: U.S. Stocks Retreat; Energy Stocks Sell Off

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad